Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KK2430 in Hematologic Neoplasms
NCT07629726Phase 2Recruiting
- Sponsor
- Kyowa Kirin
- Start
- Aug 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 2 trial of KK2430 in hematologic neoplasms, sponsored by Kyowa Kirin. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events at 1.5 years and 4 more. Started Aug 2026; status: recruiting.
02
Drugs
KK2430
03
Conditions
hematologic neoplasms
Beyond the preview
Go deeper on NCT07629726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07629726.